Streetbeat News

Price Targets

ESPR

Esperion Therapeutics (NASDAQ:ESPR) has received 4 bullish analyst ratings in the last quarter with an average price target of $15.25, indicating a significant upside from the current price of $0.9199. The average price target has risen by 69.44% over the past month, suggesting a positive outlook from analysts on the stock.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 6:00 pm

OSK

Oshkosh (NYSE:OSK) has received 5 analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, and 1 indifferent. No bearish ratings were reported. The average price target for OSK is $114.2, representing an upside from the current price of $94.31. The target has increased by 2.27% over the past month. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company risk profiles.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 6:00 pm

CTSH

Cognizant Tech Solns Inc. (NASDAQ:CTSH) shares are trading at $65.69, with a recent 0.40% decrease and a 2.21% drop over the past month, despite a 9.55% increase over the past year. The company's P/E ratio of 16.09 is lower than the IT Services industry average of 43.33, which could suggest undervaluation or weaker growth prospects. Investors are advised to consider P/E ratios among other financial metrics and industry trends for a comprehensive analysis.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 6:00 pm

GTLB

GitLab shares are trading higher following BTIG's initiation of coverage on the stock with a Buy rating and a $56 price target.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:57 pm

PX

Oppenheimer analyst Chris Kotowski has reiterated an Outperform rating on P10, which trades under the ticker PX on the NYSE, and has maintained a price target of $15 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:45 pm

MPWR

Oppenheimer analyst Rick Schafer has maintained an Outperform rating on Monolithic Power Systems (NASDAQ:MPWR) and increased the price target from $500 to $600.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:43 pm

NTLA

Oppenheimer analyst Jay Olson has maintained an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) but has reduced the price target from $80 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:34 pm

GXO

Oppenheimer analyst Scott Schneeberger has maintained an Outperform rating on GXO Logistics (NYSE:GXO) but reduced the price target from $76 to $66.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:32 pm

CTOS

Oppenheimer analyst Scott Schneeberger has maintained an Outperform rating on Custom Truck One Source (NYSE:CTOS) but has reduced the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:30 pm

CALC

Oppenheimer analyst Leland Gershell has reiterated an Outperform rating on CalciMedica (NASDAQ:CALC) and maintained a $14 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 5:28 pm